Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
allo-501 save search
Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano
Published: 2023-06-15 (Crawled : 13:00) - globenewswire.com
ALLO | $3.39 -2.31% -2.36% 1.8M
|
Health Technology
|
| O: -0.7%
H: 1.82%
C: 0.4%
allo-501 conference presentation international therapeutics
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano
Published: 2023-06-09 (Crawled : 22:00) - globenewswire.com
ALLO | $3.39 -2.31% -2.36% 1.8M
|
Health Technology
| Email alert
Add to watchlist
allo-501 conference presentation international cell therapeutics
NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting
Published: 2023-06-05 (Crawled : 12:00) - globenewswire.com
NEXI | $3.72 6.59% 6.18% 45K
|
|
| O: 8.06%
H: 0.48%
C: -9.04%
nexi-001 positive aml meeting trial
Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2023-06-03 (Crawled : 16:20) - globenewswire.com
ALLO | $3.39 -2.31% -2.36% 1.8M
|
Health Technology
| Email alert
Add to watchlist
allo-501 cell meeting therapeutics
Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress
Published: 2023-05-11 (Crawled : 15:00) - globenewswire.com
ALLO | $3.39 -2.31% -2.36% 1.8M
|
Health Technology
|
| O: 0.31%
H: 0.47%
C: -3.13%
allo-501 association presentation cell trials therapeutics
Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2023-04-26 (Crawled : 14:20) - globenewswire.com
ALLO | $3.39 -2.31% -2.36% 1.8M
|
Health Technology
|
| O: 0.18%
H: 1.96%
C: -3.21%
allo-501 presentation cell trials meeting therapeutics
Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma
Published: 2022-06-08 (Crawled : 13:00) - allogene.com
ALLO | $3.39 -2.31% -2.36% 1.8M
|
Health Technology
|
| O: 15.39%
H: 13.02%
C: 11.63%
allo-501 fda designation granted therapeutics therapy rmat
Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First TurboCAR™ T Cell Product Candidate, for the Treatment of Multiple Myeloma
Published: 2022-04-27 (Crawled : 14:00) - biospace.com/
ALLO | $3.39 -2.31% -2.36% 1.8M
|
Health Technology
|
| O: -0.24%
H: 3.32%
C: -0.59%
allo-605 treatment fda designation therapeutics
Allogene Therapeutics Reports Third Quarter 2021 Financial Results and Business Update
Published: 2021-11-04 (Crawled : 01:00) - biospace.com/
ALLO | $3.39 -2.31% -2.36% 1.8M
|
Health Technology
|
| O: 4.4%
H: 0.0%
C: 0.0%
financial results results
Allogene Therapeutics Granted FDA Fast Track Designation for ALLO-605, the First TurboCAR™ T Cell Therapy, for the Treatment of Relapsed/Refractory Multiple Myeloma
Published: 2021-06-30 (Crawled : 13:00) - biospace.com/
ALLO | $3.39 -2.31% -2.36% 1.8M
|
Health Technology
|
| O: 0.44%
H: 4.62%
C: 3.08%
treatment fda fda fast track fast track therapy fast track designation t-cell designation
Allogene Therapeutics Presents Positive Phase 1 Data on ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 Annual Meeting of the American Society of Clinical Oncology
Published: 2021-06-04 (Crawled : 13:00) - globenewswire.com
ALLO | $3.39 -2.31% -2.36% 1.8M
|
Health Technology
|
| O: 1.09%
H: 0.56%
C: -2.15%
phase 1 positive phase 3
Allogene Therapeutics CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021
Published: 2021-05-19 (Crawled : 21:00) - globenewswire.com
ALLO | $3.39 -2.31% -2.36% 1.8M
|
Health Technology
|
| O: 11.52%
H: 0.06%
C: -15.43%
positive results phase 1 positive results phase 3
Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR™ Candidate, for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma
Published: 2021-04-19 (Crawled : 13:00) - globenewswire.com
ALLO | $3.39 -2.31% -2.36% 1.8M
|
Health Technology
|
| O: -1.54%
H: 1.91%
C: 1.03%
food treatment drug clearance
Allogene Therapeutics Presents Preclinical Findings Supporting ALLO-605, the First Anti-BCMA TurboCAR™ T Cell Therapy, at the 62nd Meeting of the American Society of Hematology
Published: 2020-12-07 (Crawled : 15:01) - globenewswire.com
ALLO | $3.39 -2.31% -2.36% 1.8M
|
Health Technology
|
| O: -0.09%
H: 0.09%
C: -13.56%
therapy t-cell preclinical pre-clinical
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.